Maximum allowable cost: can the government control drug costs?

Area of Science:

• Health Policy
• Pharmaceutical Economics
• Government Regulation

Background:

• Federal drug reimbursement policies were established in 1973 to control pharmaceutical costs.
• The policy mandated reimbursement at the lowest available drug cost, barring significant therapeutic differences between brands and generics.

Purpose of the Study:

• To analyze the political history and justification behind the 1973 federal drug cost-containment program.
• To explore controversies surrounding government-funded drug benefit programs.
• To anticipate pharmaceutical industry responses to price control measures.

Main Methods:

• Historical analysis of the 1973 drug reimbursement policy.
• Examination of the political and economic rationale for the program.
• Review of ongoing debates on public drug financing.

Main Results:

• The 1973 policy represented an early governmental effort to regulate pharmaceutical prices.
• The program's success was anticipated to provoke counter-strategies from the pharmaceutical industry.
• Potential industry tactics could diminish the intended cost-saving benefits of the program.

Conclusions:

• The 1973 drug cost-control initiative was a significant policy intervention.
• Anticipated pharmaceutical industry responses pose a threat to the program's efficacy.
• The long-term impact of such policies on drug pricing and access remains a critical issue.